Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy and Safety of REL-1017 Monotherapy for Major Depressive Disorder

NCT05081167 is registered in ClinicalTrials.gov with Relmada Therapeutics, Inc. as lead sponsor.

NCT NCT05081167
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05081167 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy and Safety of REL-1017 Monotherapy for Major Depressive Disorder
Lead sponsor
Relmada Therapeutics, Inc.
Phase
Phase 3
Overall status
Completed
Start date
June 2, 2021
Completion date
September 14, 2022
Enrollment
232 (actual)
Sites
10

Conditions

As the registry lists them; a condition with its own page is linked.

major depressive disorder